Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study to Evaluate the Safety and Efficacy of Pacritinib in Relapsed or Refractory Waldenström Macroglobulinemia

NCT06986174 is registered in ClinicalTrials.gov with Shayna Sarosiek, MD as lead sponsor.

NCT NCT06986174
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06986174 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study to Evaluate the Safety and Efficacy of Pacritinib in Relapsed or Refractory Waldenström Macroglobulinemia
Lead sponsor
Shayna Sarosiek, MD
Phase
Phase 2
Overall status
Recruiting
Start date
November 21, 2025
Completion date
October 1, 2032
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

b-cell lymphoproliferative disorder, indolent lymphoma, lymphoplasmacytic lymphoma, waldenström macroglobulinemia